BNP Paribas restated their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Thursday. BNP Paribas currently has a GBX 1,560 ($21.55) price target on the stock.
Several other analysts have also commented on GSK. Morgan Stanley upgraded shares of GlaxoSmithKline from an underweight rating to an equal rating and raised their price objective for the stock from GBX 1,300 ($17.96) to GBX 1,400 ($19.34) in a report on Thursday. Societe Generale restated a sell rating and issued a GBX 1,130 ($15.61) price objective on shares of GlaxoSmithKline in a report on Wednesday, March 14th. Liberum Capital restated a buy rating and issued a GBX 1,630 ($22.52) price objective on shares of GlaxoSmithKline in a report on Thursday, March 8th. Goldman Sachs set a GBX 1,750 ($24.18) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Friday, March 2nd. Finally, HSBC restated a buy rating and issued a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 1,529.55 ($21.13).
Shares of GlaxoSmithKline stock opened at GBX 1,315.60 ($18.18) on Thursday. The stock has a market capitalization of $65,630.00 and a PE ratio of 2,482.26. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($17.07) and a 12 month high of GBX 1,724.50 ($23.83).
In related news, insider Patrick Vallance sold 14,022 shares of the firm’s stock in a transaction that occurred on Monday, February 19th. The shares were sold at an average price of GBX 1,318 ($18.21), for a total transaction of £184,809.96 ($255,332.91). Also, insider Sir Roy Anderson purchased 562 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, February 7th. The shares were purchased at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Over the last quarter, insiders have bought 591 shares of company stock valued at $756,678 and have sold 23,765 shares valued at $31,152,709.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.